<DOC>
	<DOCNO>NCT01302327</DOCNO>
	<brief_summary>Wolfram syndrome , also refer DIDMOAD ( diabetes insipidus , diabetes mellitus , optic atrophy deafness ) genetic syndrome characterize beta-cell dysfunction apoptosis lead diabetes , neurodegeneration psychiatric illness . Accumulating evidence indicate beta-cell failure neuronal cell dysfunction Wolfram 's syndrome result high level ER stress affect cell . The current treatment Wolfram syndrome insulin , fail prevent progression beta-cell failure . Several study show GLP-1 analog effective protect beta-cells ER stress . Herein , investigator suggest study impact GLP-1 analog treatment patient Wolfram syndrome . The investigator Study effect GLP-1 analog ( Exanatide ) beta-cell function glycemic control patient Wolfram syndrome . Evaluation beta cell function do perform meal test IVGTT test start GLP-1 therapy , 3 month treatment .</brief_summary>
	<brief_title>GLP Analogs Diabetes Wolfram Syndrome Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Wolfram Syndrome</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Genetic definitive clinical diagnosis Wolfram 's syndrome include : diabetes mellitus , optic atrophy least one additional neurological dysfunction ( diabetes insipidus , sensorineural deafness , neurogenic bladder type autonomic peripheral neuropathy ) 2 . Age &gt; 18 year 3 . Duration diabetes &lt; 10 year . 1. pregnant woman 2. patient unable give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Wolfram syndrome</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Exenatide</keyword>
	<keyword>GLP-1 analog</keyword>
	<keyword>beta cell function</keyword>
</DOC>